Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
Felmetatug vedotin’s exit could be bad news for Mersana.
AstraZeneca bags three of the month’s four oncology approvals.
